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Taking Rhein as the lead compound, ten esters of rhein were 
synthesized by esterification. For synthesis of smaller steric 
hindrance alcohols, SOCl2 was used as a catalyst to synthesize 
methyl, ethyl and butyl esters. For lager steric hindrance alcohols, 
dicyclohexyl carbodiimide (DCC) was used as dehydrating agent, 
and 4-dimethylaminopyridine (DMAP) was used as the catalyst to 
synthesize isopropyl, isobutyl, tertbutyl, isoamyl, benzyl, 2-phenyl 
ethyl, 2-chloroethyl esters. Structural characterization of the target 
compounds were done using melting point, 1H NMR, 13C NMR and 
HRMS. Five out of the 10 compounds were new. All the 
compounds were evaluated for antitumor activities in vitro against 
Hela human cervical carcinoma cell lines. Study found that all the 
ten compounds showed differences in their growth inhibitory effect 
on tumor cells. Compound with benzyl groups improved the 
antitumor activity. Results showed that compound 3b exhibited 
maximum activity against Hela cell lines at 100 μg mL–1 (IC50 
value) with an inhibition rate of 70%, while the derivative 3i 
showed the lowest inhibitory activity (IC50 <64.3 μg mL
–1). 
Keywords: Anticancer, Antitumor, DMAP, Ester derivatives, 
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For humans, cancer is one of the most important life 
threatening diseases. As much as 8.1 million people are 
reported to be suffering from cancer that accounts for 
16% of total deaths worldwide. Asia leads both in 
cancer incidence (57.3%) and cancer mortality 
(48.4%). It is reported that United States would 
approximately record 1.81 million new cancer cases 
and 0.61 million deaths in 2020
1-3
. In drug research, 
plants serve as the natural reservoir of innumerable 
bioactive components exhibiting various toxic as well 
as beneficial properties. Newman et al.
4
 found that 
more than 60% new chemical entities of small 
molecules are drugs sourced from the wild plants. 
Rhein, a main constituent of rhubarb isolated from 
Rheum spiciforme, belongs to the hydroxyl group, and 
its anthraquinone derivatives represent a wide range of 
anti-inflammatory, antioxidant, antiviral, hypoglycemic, 
lipid-lowering effects and pharmacological activities
5-10
. 
More importantly, rhein has significant resistance, 
tumor activity and synergistic anti-tumor potential
11-13
. 
Numerous reports show that anthraquinone derivatives 
can be used as antitumor drugs
5,7,14
. Drugs with 
anthraquinone structure as pharmacophore have 
become an important class of clinical anticancer drugs, 
such as doxorubicin, mitoxantrone, etc. (Fig. 1).  
 
Doxorubicin mainly affects topoisomerase enzyme 
II activity to show its an anti-tumor effects. 
Mitoxantrone is a DNA intercalator, which can 
intercalate into DNA bases and blocks DNA synthesis 
and transcription
15
. Intermittently, doxorubicin can 
inhibit DNA topoisomerase II, causes unwinding of 
genomic DNA. Therefore, Rhein can be used as a 
potential lead in finding anti-tumor drugs. Available 
research is mainly focused on pharmacological 
properties of rhein, and its derivatization at 3-position 
structure, and the simultaneous derivatization of its 
1,8- and 3- position
16,17
. The current study involves 
derivatization of 1,8 position of rhein. Besides, it also 
focuses on its tumor activity and ability to interact 
with DNA which are expected to enhance the series 
solubility of the drug and relieve the cytotoxicity of 
the drug, and improve its bioavailability rate. 
 
Materials and Methods 
 
Instruments and reagents 
Bruker Avance III HD 400 nuclear magnetic 
resonance instrument (CDCl3 or DMSO- d 6 is the 




Fig. 1 — Chemical structures of doxorubicin, mitoxantrone and rhein. 
 




melting point instrument (Shanghai Precision 
Scientific Instrument Co., Ltd. Division); Full 
Automatic polarimeter (Rudolph Autopol V); silica 
gel for column chromatography (200～300 mesh, 
Qingdao Ocean Chemical Co., Ltd.); and IC50 
concentration calculation software is Origin 9.0 were 
used in the study. All chemicals of analytical grade 
were purchased from Yu Aladdin Reagents 
(Shanghai) Co., Ltd. and Adamas reagent company 
Ltd. (Shanghai). 
 
Synthesis of compounds 
Dissolve rhein (5 mmol) in absolute ethanol 20 mL 
as a solvent and add 5 mL of SOCl2 and DMAP as a 
catalyst in a 100 mL round bottom flask and heat at 
80-90℃. After 24 h, the raw material was completely 
converted. Reaction solution was poured directly into 
500 mL of distilled water, followed by suction 
filtration, and washed the solid with a large amount of 
distilled water, solid was fully dried in a vacuum 
drying oven to obtain 1.464 g of compound 2 (yield 
95%). Then compound 2 was added in 100 mL round 
bottom flask (1.0 mmol, 312 mg), DMF 50 mL, then 
slowly NaH (5 mmol, 120 mg) was added after 
changing the color of reaction. Excess amount of 
iodine/bromoalkane hydrocarbon (6 mmol) was added 
carefully. The reaction liquid is heated to 100-120℃ 
to react to the raw material point disappears and it 
was monitoring by TLC. After the reaction, the 30mL 
(1.0 mol/L) of HCl was added to the reaction mixture, 
and the aqueous solution was extracted using 
dichloromethane, and the organic phase was 
collected. The product obtained by column 
chromatography [Eluent (hexane): (ethyl acetate) = 
5:1] and the solid product was obtained after rotary 
evaporation under reduced pressure. In 50 mL RBF, 
the crude product was collected and 20 mL (1.0 mol/L) 
NaOH aqueous solution was added at room 
temperature (25℃) to 60℃. Stir and monitor the 
progress of the reaction by TLC till completion of 
hydrolysis. Then, 1.0 mol/L HCl was used to adjust 
the pH of the aqueous solution (5-6 pH). After 
reaching pH 5-6 the product was precipitated and 
filter using suction, washed the obtained solid product 
with deionized water, and dryed it. The yellow solid 
obtained (3a-3j) having the yield is 46～86%.  
 
In vitro anti-tumor activity test 
Cells at about 10.5 mg/mL density were seeded in 
96-well plates, each well was inoculated with 100 μL 
and incubate in a CO2 incubator until the logarithmic 
growth phase. The samples were tested as per 
concentration gradient, and test was repeated three 
times for each gradient. The control group was added 
an equal volume of solvent for dissolving the sample. 
After 48 h of incubation, 20 μL of MTT (5 mg/mL) 
were added to each well, and then place at 37℃ for  
4 h for incubation. After removing the supernatant, 
100 μL of DMSO was added to each well and shaken 
well. The precipitate was allowed to dissolve for 10 min, 
and then checked for optical density (OD) value with 
a microplate reader at a wavelength of 490 nm. 
Following formula was used to find the cell survival 
rate at a certain concentration of the sample:  
 
Survival rate (%) =
Average OD value of the sample group
Average OD of the control group value
× 100 
 
The cell survival rate was plotted against the 
logarithm of the drug concentration, and drawing 
method was used to calculate IC50 value for each 
sample. 
 
Results and Discussion 
 
Compound synthesis and their structure 
As shown in Scheme 1 for the synthesis of targeted 
molecules, rhein (1) was used as the starting material, 
SOCl2/DMAP as a catalyst in ethanol as a solvent 
under reflux conditions for esterification reaction
18
. 
Highly substituted or halogenated alkanes ring gave 
more yield and stability in the presence of DMAP 
with respect to SOCl2. Ethyl rhein 2 was obtained, 
which reacted with different halogenated 
hydrocarbons in the presence of strong base sodium 
hydride. Ether was formed under the hydrolysis of the 
ester to obtain 1,8-dialkoxy rhein (3a-j). The structure 





C NMR, and HRMS. 
 
Analysis of target compound (3a-j) 
 
3a. 4,5-dimethoxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid 
Yellow solid, yield 84%. mp 218.8～221.7℃; 1H 




Scheme 1: Synthesis route of the target compound [reagents and 
conditions: (i) SOCl2, EtOH, reflux; (ii) R1X, NaH, DMF,  
100-120℃; (iii) 1mmol/L DCC (aq.), RT to 60℃; then 1 mol/L 






1.5 Hz, 1 H), 7.82 (d, J = 7.6, Hz, 1 H), 7.67 (s, J = 1.5 
Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.84 (t, J =7.4 Hz,  
1 H), 3.90 (s, J = 7.6, 3 H). 
13
C NMR (CDCl3, 400 
MHz): d 182.2, 182.2, 159.8, 160.1, 120.5, 125.4, 131.2, 
135.8, 134.5, 123.0, 119.1, 120.4, 117.6, 133.2, 169.3, 




3b. 4, 5-diethoxy-9, 10-dioxo-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 218.8～223.7℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1 H), 7.95 (s, J = 
1.5 Hz, 1 H), 7.82 (d, J = 7.6, Hz, 1 H), 7.67 (s, J =  
1.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.84 (t, J = 
7.4 Hz, 1 H), 4.5 (t, J = 8.0, 2 H), 1.34 (m, J = 8.0, 3 H). 
13
C NMR (CDCl3, 400 MHz): d 182.2, 182.2, 158.3, 
157.8, 124.7, 125.4, 130.6, 135.4, 134.3, 123.3, 118.4, 
119.7, 117.9, 132.4, 169.3, 64.7, 64.7, 14.7, 14.7 and 




3c. 4, 5-dibutoxy-9, 10-dioxo-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 215.8～220.7℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1H), 7.95(s, J =  
1.5 Hz, 1 H), 7.82 (d, J = 7.6, Hz, 1 H), 7.67 (s, J = 1.5 
Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.84 (t, J =7.4 Hz,  
1 H), 4.5 (t, J = 7.1 2 H), 1.74 (m, J = 7.1, 2 H), 1.47 (m, 
J = 7.1-8.0 2 H), 0.96 (t, J = 8.0, 3 H). 
13
C NMR 
(CDCl3, 400 MHz): d 182.3, 182.3, 158.0, 157.7, 124.6, 
125.3, 130.6, 135.4, 134.2, 123.5, 118.2, 119.7, 117.8, 
132.7, 169.5, 68.2, 68.2, 31.7, 31.7, 19.3, 19.3, 14.1, 




3d. 4, 5-bis(benzyloxy)-9, 10-dioxo-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 217.8～224.7℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1 H), 7.95 (s, J = 
1.5 Hz, 1 H), 7.82 (t, J = 7.6, Hz, 1 H), 7.67 (s, J =  
1.5 Hz, 1 H), 7.47(d, J = 7.5-1.5 Hz, 1 H), 7.3 (d, J = 
7.5-1.5 Hz, 1 H), 7.3 (t, J =7.4 Hz, 1 H), 7.40 (tt, J = 
7.5-1.5, 1 H), 7.34 (t, J = 7.5-1.5, 1 H), 5.16 (s, 3 H). 
13
C NMR (CDCl3, 400 MHz): d 182.2, 182.2, 161.4, 
161.2, 120.4, 125.5, 131.2, 135.9, 134.5, 136.7, 136.6, 
133.0, 119.4, 120.2, 127.3, 127.3, 133.2, 128.8, 128.9, 
128.8, 128.9, 127.6, 127.6, 169.2, 70.8, 70.8 and 




3e. 4, 5-diisopropoxy-9, 10-dioxo-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 218.8～225.7℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1 H), 7.95(s, J = 
1.5 Hz, 1 H), 7.82 (d, J = 7.6, Hz, 1 H), 7.67 (s, J = 
1.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.85 (t, J = 
7.4 Hz, 1 H), 4.69 (m, J = 6.8, 1 H), 1.31 (dd, J = 6.8, 
3 H). 
13
C NMR (CDCl3, 400 MHz): d 182.2, 182.0, 
158.2, 157.8, 121.5, 125.2, 130.1, 135.8, 134.9, 123.1, 
118.6, 119.7, 117.2, 132.7, 169.7, 75.8, 75.8, 22.3, 




3f. 4, 5-diisobutoxy-9, 10-dioxo-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 216.2～221.3℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1 H), 7.95(s, J = 
1.5 Hz, 1 H), 7.82 (d, J = 7.6, Hz, 1 H), 7.67 (s, J = 
1.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.84 (t, J =7.4 Hz, 
1 H), 3.86 (d, J = 7.0, 2 H), 1.82 (m, J = 6.8, 1 H), 0.61 (d, 
J = 6.8, 3H). 
13
C NMR (CDCl3, 400 MHz): d 182.4, 
182.4 158.3, 157.8, 124.6, 125.8, 130.6, 135.4, 134.6, 
123.8, 118.4, 119.8, 117.4, 132.6, 169.3, 74.6, 74.6, 28.3, 




3g. 4, 5-di-tert-butoxy-9, 10-dioxo-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 219.8～226.5℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1 H), 7.96 (s, J = 
1.5 Hz, 1 H), 7.82 (d, J = 7.6, Hz, 1 H), 7.65 (s, J = 
1.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.84 (t, J = 
7.4 Hz, 1 H), 1.43(s, J = 7.6, 3 H), 71.43 (s, J = 7.6). 
13
C NMR (CDCl3, 400 MHz): d 182.2, 182.2, 158.2, 
157.7, 120.9, 125.7, 130.3, 135.6, 134.2, 123.6,, 118.7, 
119.2, 117.3, 132.7, 169.5, 86.0, 86.0, 27.8, 27.8, 27.8, 




3h. 4, 5-bis(isopentyloxy)-9, 10-dioxo-9, 10-dihydroanthracene-
2-carboxylic acid 
Yellow solid, yield 84%. mp 217.5～222.7℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1 H), 7.96 (s, J = 
1.5 Hz, 1 H), 7.83 (d, J = 7.6, Hz, 1 H), 7.65 (s, J = 
1.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.84 (t, J =7.4 Hz, 
1 H), 4.05 (t, J = 7.1, 2 H), 1.81 (m, J = 7.0, 3 H), 1.66 
(m, J = 7.1 Hz, 2 H), 0.97 (d, J = 6.8 Hz, 3 H). 
13
C NMR 
(CDCl3, 400 MHz): d 182.3, 182.3, 158.2, 157.8, 124.5, 
125.3, 130.6, 135.4, 134.7, 123.2, 118.5, 119.3, 117.6, 
132.4, 169.2, 65.8, 65.8, 24.3, 24.3, 39.4, 39.4, 23.1, 
23.1, 23.1, 23.1 and HRMS[M + H]+ 396.1543. 
 
3i. 9, 10-dioxo-4, 5-diphenethoxy-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 214.2～220.7℃; 1H 
NMR (CDCl3, 400 MHz) δ 12.74 (s, 1 H), 7.96 (s, J = 
1.5 Hz, 1 H), 7.82 (d, J = 7.6, Hz, 1 H), 7.65 (s, J = 1.5 
Hz, 1 H), 7.21 (d, J = 7.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 
H), 7.21 (d, J = 7.5 Hz, 1 H), 7.84 (t, J =7.4 Hz, 1 H), 
7.23 (t, J = 7.5, 1 H), 7.23 (t, J = 7.5, 1 H) 7.19 (t, J = 
7.5, 1 H), 4.27 (t, J = 7.1 Hz, 2 H), 3.10 (t, J = 7.1 Hz, 2 






C NMR (CDCl3, 400 MHz): d 182.1, 182.1. 158.3, 
157.7, 124.5, 125.8, 130.6, 135.4, 134.3, 138.4, 138.4, 
123.6, 115.3, 119.5, 127.6, 127.6, 117.9, 127.5, 127.5, 
132.7, 128.5, 128.5, 128.5, 128.5, 125.7, 125.7, 169.3, 
67.2, 67.2, 35.3, 35.3 and HRMS [M + H]+ 379.9835. 
 
3j. 4, 5-bis(2-chloroethoxy)-9, 10-dioxo-9, 10-dihydroanthracene-2-
carboxylic acid 
Yellow solid, yield 84%. mp 219.1～227.7℃; 1H 
NMR (CDCl3 , 400 MHz) δ 12.74 (s, 1 H), 7.96 (s, J 
= 1.5 Hz, 1 H), 7.82 (d, J = 7.6 Hz, 1 H), 7.65 (s, J = 
1.5 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.84 (t, J =7.4 
Hz, 1 H), 4.09 (t, J = 7.1, 2 H), 4.22 (t, J = 7.0, 2 H), 
13
C NMR (CDCl3, 400 MHz): d 182.2, 182.2, 158.2, 
157.8, 124.5, 125.7, 130.6, 135.4, 134.1, 123.2, 118.4, 
119.5, 117.5 132.5, 42.6, 42.6, 169.2, 75.1, 75.1 and 




Biological activity of pure molecules using MTT assay and  
in vitro anti-tumor activity test 
 
Anti-tumor activity based on structural analysis 
The colorimetric method of tetramethyl azozole 
(MTT) was used to colour the target compound (3a-j) 
and were tested for in vitro antitumor activity. 
Cisplatin and amycin were used as the positive 
control. The substrate scope of the target compounds 
is shown in Table 1. 
All the derivatives did not show noticeable 
resistance to tumor activity. The isobutyl (3f) and 
isoamyl (3h) showed significant antitumor activity 
compared to other derivatives in the same series. For 
the compound with benzyl groups, the antitumor 
activity of all derivatives was further improved and 
the entire series showed general inhibitory activity  
in Hela human cervical carcinoma cell lines. 
Tikhomirov et al.
19
 found that anthraquinone 
derivative (anthracene-9,10-dione) represent an 
exceptionally valuable class in anticancer drug 
development. It was also established that chemical 
structure modifications helps in optimization of the 
anticancer properties of natural compounds.  
 
In vitro anti-tumor activity basis of IC50 value 
Compounds 3a-e showed IC50 >100 μg mL
–1
, while as 
compounds 3f-j showed IC50 <100 μg mL
–1
. Results 
showed that compound 3b exhibited high activity 
against Hela cell line at IC50 value  
>100 μg mL
–1
 and an inhibition rate is of 70%. The 
derivative 3i showed lowest inhibitory activity  
(IC 50<64.3 μg mL
–1
) when tested on Hela human 
cervical carcinoma cell lines. The IC50 value for each 
sample is shown in Table 2. 
Conclusions 
The current study used rhein as raw material, and 
carried out its esterification, alkylation, hydrolysis, 
condensation in different steps. Then, ten esters 
derivatives of rhein were designed and synthesized. 
Structural conformation was carried out for this series 





C NMR and HRMS. MTT assay 
was used to study the effect of compounds on cervical 
cancer cells (Hela). Results showed that compound 3b 
exhibited high activity against Hela cell line at  
IC50 value >100 μg mL
–1 
 and an inhibition rate is of 
70%, while as compound 3i showed lowest inhibitory 
activity (IC50 <64.3 μg mL
-1
). Study found that  
all the ten compounds showed differences in their 
growth inhibitory effect on tumor cells. Compound 
with benzyl groups showed improved the  
antitumor activity. 
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